IMRN vs KZIA
Immuron Limited and Kazia Therapeutics Limited., side by side — 8 fiscal years reported in AUD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | IMRN | KZIA |
|---|---|---|
| Revenue | AUD 7.3M | AUD 42,000 |
| Net income | AUD -5.2M | AUD -20.7M |
| Gross margin | 65.4% | — |
| Net margin | −71.6% | −49290.5% |
| Return on equity | — | −2634.3% |
| Diluted EPS | −AUD 2.26 | −AUD 0.04 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | AUD -5.9M | AUD -11.4M |
| Equity | — | AUD -8.3M |
| Net debt / equity | — | — |
| Current ratio | 5.09× | 0.35× |
| Revenue CAGR 5y | 23.7% | — |
| Profit CAGR 5y | — | — |
IMRN bills 173.5× the revenue of KZIA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
8 years side by side
| Fiscal year | IMRN | KZIA |
|---|---|---|
| FY2024 | AUD 7.3M | AUD 42,000 |
| FY2023 | AUD 4.9M | AUD 2.3M |
| FY2022 | AUD 1.8M | AUD 0 |
| FY2021 | AUD 765,193 | AUD 0 |
| FY2020 | AUD 145,776 | AUD 15.2M |
| FY2017 | AUD 1.8M | AUD 119,000 |
| FY2016 | AUD 1.4M | AUD 249,000 |
| FY2015 | AUD 1.0M | AUD 406,000 |
Net income by year
Bottom line
| Fiscal year | IMRN | KZIA |
|---|---|---|
| FY2024 | AUD -5.2M | AUD -20.7M |
| FY2023 | AUD -6.9M | AUD -26.8M |
| FY2022 | AUD -3.8M | AUD -20.5M |
| FY2021 | AUD -2.9M | AUD -25.0M |
| FY2020 | AUD -8.4M | AUD -8.4M |
| FY2017 | AUD -3.1M | AUD -6.0M |
| FY2016 | AUD -6.8M | AUD -10.7M |
| FY2015 | AUD -7.1M | AUD -12.1M |
Advertisement
AdSense · Rectangle 336×280